Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective,...

Area of Science:

• Anesthesiology
• Neurology
• Pharmacology

Background:

• Neuromuscular blockade is essential for managing muscle contractions during electroconvulsive therapy (ECT).
• Determining the minimum effective dose (MED) of neuromuscular blocking agents is crucial for patient safety and procedural efficacy.
• Succinylcholine and rocuronium are commonly used agents, but their optimal ECT doses require precise definition.

Purpose of the Study:

• To establish the minimum effective dose (MED) of succinylcholine and rocuronium for electroconvulsive therapy (ECT).
• To compare the efficacy of succinylcholine and rocuronium in achieving adequate neuromuscular blockade during ECT.
• To provide evidence-based dosing guidelines for neuromuscular blocking agents in ECT.

Main Methods:

• A crossover, assessor-blinded, prospective randomized study design was employed.
• The minimum effective dose (MED) was defined as the lowest dose providing acceptable control of muscle strength during induced convulsions.
• Doses were adjusted based on blinded psychiatrists' assessments of muscle contraction control, with quantitative neuromuscular transmission monitoring.

Main Results:

• The MED for succinylcholine was 0.85 mg/kg (MED50ECT) and 1.06 mg/kg (MED90ECT).
• The MED for rocuronium was 0.41 mg/kg (MED50ECT) and 0.57 mg/kg (MED90ECT).
• Nadir twitch height and time to recovery differed significantly between the two agents, with succinylcholine showing faster recovery.

Conclusions:

• A twitch suppression of >90% is necessary for effective motor contraction control in ECT.
• Recommended succinylcholine dosing ranges from 0.77 to 1.27 mg/kg based on patient factors.
• Rocuronium, particularly in combination with neostigmine, offers a safe alternative when dosed and monitored appropriately (0.36-0.6 mg/kg).